Nevertheless, the overall responsive rate to Ibrutinib in ABC DLBCL is only 37% (21), and this can partly be explained by mutations downstream of BCR or MYD88 (16, 29–33). The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.